Xiaofeng Li
Jiangsu University(CN)Nanchang University(CN)Shandong University(CN)Dalian Medical University(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)First Affiliated Hospital of Jiangxi Medical College(CN)Xuzhou Cancer Hospital(CN)Shanghai Public Health Clinical Center(CN)Fu Wai Hospital(CN)First Affiliated Hospital of Nanchang University(CN)China Agricultural University(CN)
Publications by Year
Research Areas
Radiomics and Machine Learning in Medical Imaging, Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes, Cancer Cells and Metastasis
Most-Cited Works
- → Chronic inflammation‐elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance(2017)126 cited
- → Characteristics of liver cancer stem cells and clinical correlations(2015)84 cited
- → 18F-Fluoromisonidazole in tumor hypoxia imaging(2017)81 cited
- → Discovery, Structure−Activity Relationship, and Pharmacological Evaluation of (5-Substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as Potent Dipeptidyl Peptidase IV Inhibitors(2006)61 cited
- → Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly(ADP-ribose) Polymerase(2011)60 cited
- → Discovery of ((4R,5S)-5-Amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a Highly Potent, Selective, Orally Efficacious, and Safe Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes